Why ACB Has Not Yet Lived Up To Its NYSE Potential.Investors can see right through Aurora's dilution, their measly global footprint, the lack of big pharma investment, and the way they conduct themselves with potential suitors. Aphria does not face these problems. Aphria will emerge on top. GLTA ._7